Toru Takenaka
Overview
Explore the profile of Toru Takenaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanada R, Takenaka T
Clin Pharmacol Drug Dev
. 2025 Jan;
14(3):200-208.
PMID: 39840517
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion...
2.
Yamamiya I, Hunt A, Takenaka T, Sonnichsen D, Mina M, He Y, et al.
Clin Pharmacol Drug Dev
. 2023 May;
12(10):966-978.
PMID: 37132707
Futibatinib, a selective, irreversible fibroblast growth factor receptor 1-4 inhibitor, is being investigated for tumors harboring FGFR aberrations and was recently approved for the treatment of FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma....
3.
Araki H, Takenaka T, Takahashi K, Yamashita F, Matsuoka K, Yoshisue K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Dec;
11(5):604-615.
PMID: 34951129
TAS-114 is a dual deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD) inhibitor expected to widen the therapeutic index of capecitabine. Its maximum tolerated dose (MTD) was determined from a safety...
4.
Kumagai Y, Fujita T, Maeda M, Sasaki Y, Nagaoka M, Huang J, et al.
J Clin Pharmacol
. 2020 Feb;
60(6):702-710.
PMID: 32026490
TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d ] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a physiologically based...
5.
Yoshimura C, Muraoka H, Ochiiwa H, Tsuji S, Hashimoto A, Kazuno H, et al.
Mol Cancer Ther
. 2019 May;
18(7):1205-1216.
PMID: 31092565
NEDD8-activating enzyme (NAE) is an essential E1 enzyme of the NEDD8 conjugation (neddylation) pathway, which controls cancer cell growth and survival through activation of cullin-RING ubiquitin ligase complexes (CRL). In...
6.
Takenaka T, Kazuki K, Harada N, Kuze J, Chiba M, Iwao T, et al.
Drug Metab Pharmacokinet
. 2017 Feb;
32(1):61-68.
PMID: 28139373
The Caco-2 cells co-expressing cytochrome P450 (CYP) 3A4 and NADPH-cytochrome P450 reductase (CPR) were developed using a human artificial chromosome (HAC) vector. The CYP3A4 and CPR genes were cloned into...
7.
Takenaka T, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T
J Pharm Sci
. 2016 Feb;
105(2):915-924.
PMID: 26869436
A human small intestinal epithelial cell (HIEC) monolayer was recently established in our laboratories as a novel system to evaluate the Papp (apparent permeability coefficient) of compounds during their absorption...
8.
Takenaka T, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T
Drug Metab Dispos
. 2014 Sep;
42(11):1947-54.
PMID: 25200868
Adult intestinal stem cells (ISCs) possess both a long-term proliferation ability and differentiation capability into enterocytes. As a novel in vitro system for the evaluation of drug absorption, we characterized...
9.
Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, et al.
Mol Cancer Ther
. 2013 Oct;
12(12):2685-96.
PMID: 24140932
VEGF receptor (VEGFR) signaling plays a key role in tumor angiogenesis. Although some VEGFR signal-targeted drugs have been approved for clinical use, their utility is limited by associated toxicities or...
10.
Takekuma Y, Takenaka T, Yamazaki K, Ueno K, Sugawara M
Biol Pharm Bull
. 2007 Nov;
30(11):2146-53.
PMID: 17978490
Carvedilol, an alpha- and beta-adrenergic blocking drug, is mainly metabolized by CYP2D6, UGT1A1, UGT2B4 and UGT2B7. This drug is administered orally as a racemic mixture of R(+)- and S(-)-enantiomers. It...